Genetic Testing in Neurodevelopmental Disorders
Open accessThe DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
Neurodevelopmental disorders are the most prevalent chronic medical conditions encountered in pediatric primary care. In addition to identifying appropriate descriptive diagnoses and guiding families to evidence-based treatments and supports, comprehensive care for individuals with neurodevelopmental disorders includes a search for an underlying etiologic diagnosis, primarily through a genetic evaluation. Identification of an underlying genetic etiology can inform prognosis, clarify recurrence risk, shape clinical management, and direct patients and families to condition-specific resources and supports. Here we review the utility of genetic testing in patients with neurodevelopmental disorders and describe the three major testing modalities and their yields – chromosomal microarray, exome sequencing (with/without copy number variant calling), and FMR1 CGG repeat analysis for fragile X syndrome. Given the diagnostic yield of genetic testing and the potential for clinical and personal utility, there is consensus that genetic testing should be offered to all patients with global developmental delay, intellectual disability, and/or autism spectrum disorder. Despite this recommendation, data suggest that a minority of children with autism spectrum disorder and intellectual disability have undergone genetic testing. To address this gap in care, we describe a structured but flexible approach to facilitate integration of genetic testing into clinical practice across pediatric specialties and discuss future considerations for genetic testing in neurodevelopmental disorders to prepare pediatric providers to care for patients with such diagnoses today and tomorrow.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W. W., Hegde, M., Lyon, E., Spector, E., et al. (2015) · Genetics in Medicine · doi:10.1038/gim.2015.30 · Cited by 32,594
Verkerk, A. J. M. H., Pieretti, M., Sutcliffe, J. S., Fu, Y.-H., Kuhl, D. P. A., Pizzuti, A., Reiner, O., Richards, S., Victoria, M. F., Zhang, F., et al. (1991) · Cell · doi:10.1016/0092-8674(91)90397-h · Cited by 3,481 · cited 1×
“Most individuals in the general population have 44 or fewer CGG repeats, while more than 200 CGG repeats in the FMR1 gene results in hypermethylation and, consequently, transcriptional silencing of the gene (182, 183).”
BackgroundMiller, D. T., Adam, M. P., Aradhya, S., Biesecker, L. G., Brothman, A. R., Carter, N. P., Church, D. M., Crolla, J. A., Eichler, E. E., Epstein, C. J., et al. (2010) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2010.04.006 · Cited by 2,882 · cited 5×
“(ISCA) Consortium (80) • CMA is the first-tier genetic test in patients with”
BackgroundInfluentialFu, Y.-H., Kuhl, D. P. A., Pizzuti, A., Pieretti, M., Sutcliffe, J. S., Richards, S., Verkert, A. J. M. H., Holden, J. J. A., Fenwick, R. G., Warren, S. T., et al. (1991) · Cell · doi:10.1016/0092-8674(91)90283-5 · Cited by 2,080 · cited 1×
“Most individuals in the general population have 44 or fewer CGG repeats, while more than 200 CGG repeats in the FMR1 gene results in hypermethylation and, consequently, transcriptional silencing of the gene (182, 183).”
BackgroundIdentification, Evaluation, and Management of Children With Autism Spectrum Disorder
Hyman, S. L., Levy, S. E., Myers, S. M., COUNCIL ON CHILDREN WITH DISABILITIES, S. O. D. A. B. P., Kuo, D. Z., Apkon, S., Davidson, L. F., Ellerbeck, K. A., Foster, J. E. A., Noritz, G. H., et al. (2020) · Pediatrics · doi:10.1542/peds.2019-3447 · Cited by 1,798 · cited 5×
“It is also important to note that elucidating etiologies and pathophysiologic processes is a necessary step toward developing animal models and human cell lines to use in pathogenesis studies, clinical trials, and, ultimately, mechanismbased targeted treatments for neurodevelopmental disorders (13, 53).”
BackgroundInfluentialSelf-citationClinGen — The Clinical Genome Resource
Rehm, H. L., Berg, J. S., Brooks, L. D., Bustamante, C. D., Evans, J. P., Landrum, M. J., Ledbetter, D. H., Maglott, D. R., Martin, C. L., Nussbaum, R. L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmsr1406261 · Cited by 1,496 · cited 1×
“As reference databases are bolstered (317), data sharing of variants and candidate genes increases (317, 323, 324), and additional technologies such RNA-sequencing and genome-wide methylation studies are integrated into testing algorithms (317, 319), our understanding of genes’ relationship to neurodevelopment disorde…”
BackgroundMolecular Findings Among Patients Referred for Clinical Whole-Exome Sequencing
Yang, Y., Muzny, D. M., Xia, F., Niu, Z., Person, R., Ding, Y., Ward, P., Braxton, A., Wang, M., Buhay, C., et al. (2014) · JAMA · doi:10.1001/jama.2014.14601 · Cited by 1,360
Prevalence and Trends of Developmental Disabilities among Children in the United States: 2009–2017
Zablotsky, B., Black, L. I., Maenner, M. J., Schieve, L. A., Danielson, M. L., Bitsko, R. H., Blumberg, S. J., Kogan, M. D., & Boyle, C. A. (2019) · Pediatrics · doi:10.1542/peds.2019-0811 · Cited by 1,217 · cited 1×
“With a combined prevalence of ∼17% among 3- to 17-year-old children in the United States, neurodevelopmental disabilities are the most prevalent chronic medical conditions encountered in pediatric primary care (1).”
BackgroundGenetic architectures of psychiatric disorders: the emerging picture and its implications
Sullivan, P. F., Daly, M. J., & O'Donovan, M. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3240 · Cited by 1,177
Genome sequencing identifies major causes of severe intellectual disability
Gilissen, C., Hehir-Kwa, J. Y., Thung, D. T., van de Vorst, M., van Bon, B. W. M., Willemsen, M. H., Kwint, M., Janssen, I. M., Hoischen, A., Schenck, A., et al. (2014) · Nature · doi:10.1038/nature13394 · Cited by 1,125
The Diagnosis of Mental Disorders: The Problem of Reification
Hyman, S. E. (2010) · Annual Review of Clinical Psychology · doi:10.1146/annurev.clinpsy.3.022806.091532 · Cited by 1,052
Thapar, A., Cooper, M., & Rutter, M. (2017) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30376-5 · Cited by 903
Insel, T. R., & Cuthbert, B. N. (2015) · Science · doi:10.1126/science.aab2358 · Cited by 840
Zoghbi, H. Y., & Bear, M. F. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a009886 · Cited by 797 · cited 1×
“It is also important to note that elucidating etiologies and pathophysiologic processes is a necessary step toward developing animal models and human cell lines to use in pathogenesis studies, clinical trials, and, ultimately, mechanismbased targeted treatments for neurodevelopmental disorders (13, 53).”
BackgroundNeurodevelopmental model of schizophrenia: update 2012
Rapoport, J. L., Giedd, J. N., & Gogtay, N. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.23 · Cited by 790
Genetic studies in intellectual disability and related disorders
Vissers, L. E. L. M., Gilissen, C., & Veltman, J. A. (2016) · Nature Reviews Genetics · doi:10.1038/nrg3999 · Cited by 761
Srivastava, S., Love-Nichols, J. A., Dies, K. A., Ledbetter, D. H., Martin, C. L., Chung, W. K., Firth, H. V., Frazier, T., Hansen, R. L., Prock, L., et al. (2019) · Genetics in Medicine · doi:10.1038/s41436-019-0554-6 · Cited by 695
Clark, L. A., Cuthbert, B., Lewis-Fernández, R., Narrow, W. E., & Reed, G. M. (2017) · Psychological Science in the Public Interest · doi:10.1177/1529100617727266 · Cited by 688
A recurrent 16p12.1 microdeletion supports a two-hit model for severe developmental delay
Girirajan, S., Rosenfeld, J. A., Cooper, G. M., Antonacci, F., Siswara, P., Itsara, A., Vives, L., Walsh, T., McCarthy, S. E., Baker, C., et al. (2010) · Nature Genetics · doi:10.1038/ng.534 · Cited by 667 · cited 1×
“In addition to the important impact of environmental and stochastic variation, recent advances suggest that the observed variability in phenotypic expression of large-effect rare variants may be explained, in part, by the additive effects of additional high-impact variants (328, 329) and background polygenic risk conf…”
BackgroundSharp, A. J., Hansen, S., Selzer, R. R., Cheng, Z., Regan, R., Hurst, J. A., Stewart, H., Price, S. M., Blair, E., Hennekam, R. C., et al. (2006) · Nature Genetics · doi:10.1038/ng1862 · Cited by 658
The Genetic Basis of Mendelian Phenotypes: Discoveries, Challenges, and Opportunities
Chong, J. X., Buckingham, K. J., Jhangiani, S. N., Boehm, C., Sobreira, N., Smith, J. D., Harrell, T. M., McMillin, M. J., Wiszniewski, W., Gambin, T., et al. (2015) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2015.06.009 · Cited by 643
Live fast, die young? A review on the developmental trajectories of ADHD across the lifespan
Franke, B., Michelini, G., Asherson, P., Banaschewski, T., Bilbow, A., Buitelaar, J. K., Cormand, B., Faraone, S. V., Ginsberg, Y., Haavik, J., et al. (2018) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2018.08.001 · Cited by 643
Phenotypic Heterogeneity of Genomic Disorders and Rare Copy-Number Variants
Girirajan, S., Rosenfeld, J. A., Coe, B. P., Parikh, S., Friedman, N., Goldstein, A., Filipink, R. A., McConnell, J. S., Angle, B., Meschino, W. S., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200395 · Cited by 621 · cited 1×
“In addition to the important impact of environmental and stochastic variation, recent advances suggest that the observed variability in phenotypic expression of large-effect rare variants may be explained, in part, by the additive effects of additional high-impact variants (328, 329) and background polygenic risk conf…”
BackgroundClark, M. M., Stark, Z., Farnaes, L., Tan, T. Y., White, S. M., Dimmock, D., & Kingsmore, S. F. (2018) · npj Genomic Medicine · doi:10.1038/s41525-018-0053-8 · Cited by 619 · cited 1×
“Several studies suggest that the diagnostic yield of ES is higher when trios (probands and parents) are tested than when only the DNA of probands is sequenced (139, 140, 147).”
BackgroundWilliams, N. M., Zaharieva, I., Martin, A., Langley, K., Mantripragada, K., Fossdal, R., Stefansson, H., Stefansson, K., Magnusson, P., Gudmundsson, O. O., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61109-9 · Cited by 572
Schaefer, G. B., & Mendelsohn, N. J. (2013) · Genetics in Medicine · doi:10.1038/gim.2013.32 · Cited by 537
Neurodevelopmental hypothesis of schizophrenia
Owen, M. J., O'Donovan, M. C., Thapar, A., & Craddock, N. (2011) · British Journal of Psychiatry · doi:10.1192/bjp.bp.110.084384 · Cited by 500
Study, S. S., Singh, T., Study, I., Study, D., UK10 K Consortium, Kurki, M. I., Curtis, D., Purcell, S. M., Crooks, L., McRae, J., et al. (2016) · Nature Neuroscience · doi:10.1038/nn.4267 · Cited by 452
Kaminsky, E. B., Kaul, V., Paschall, J., Church, D. M., Bunke, B., Kunig, D., Moreno-De-Luca, D., Moreno-De-Luca, A., Mulle, J. G., Warren, S. T., et al. (2011) · Genetics in Medicine · doi:10.1097/gim.0b013e31822c79f9 · Cited by 437 · cited 1×
“2 recurrent microdeletion that causes Smith-Magenis syndrome (83, 84), or novel gains or losses that impact dosage sensitive gene(s).”
BackgroundTammimies, K., Marshall, C. R., Walker, S., Kaur, G., Thiruvahindrapuram, B., Lionel, A. C., Yuen, R. K. C., Uddin, M., Roberts, W., Weksberg, R., et al. (2015) · JAMA · doi:10.1001/jama.2015.10078 · Cited by 419 · cited 2×
“Lower IQ, dysmorphic features, and congenital anomalies have been found to be associated with higher diagnostic yield of CMA and ES in some studies examining yield in patients with ASD (111, 113, 146, 198, 201).”
BackgroundCommon genetic variants contribute to risk of rare severe neurodevelopmental disorders
Niemi, M. E. K., Martin, H. C., Rice, D. L., Gallone, G., Gordon, S., Kelemen, M., McAloney, K., McRae, J., Radford, E. J., Yu, S., et al. (2018) · Nature · doi:10.1038/s41586-018-0566-4 · Cited by 340
Genomics, Intellectual Disability, and Autism
Mefford, H. C., Batshaw, M. L., & Hoffman, E. P. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1114194 · Cited by 329 · cited 3×
“While ES identifies 100–200 potentially deleterious sequence variants on average, more targeted analysis identifies a smaller number of variants requiring less analysis and reducing the potential for variants of uncertain significance (81, 120, 154).”
BackgroundClashing diagnostic approaches: DSM-ICD versus RDoC
Lilienfeld, S. O., & Treadway, M. T. (2016) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-021815-093122 · Cited by 275
De novo mutations in regulatory elements in neurodevelopmental disorders
Short, P. J., McRae, J. F., Gallone, G., Sifrim, A., Won, H., Geschwind, D. H., Wright, C. F., Firth, H. V., FitzPatrick, D. R., Barrett, J. C., et al. (2018) · Nature · doi:10.1038/nature25983 · Cited by 274 · cited 1×
“It is estimated that up to 3% of all patients with negative exomes could be explained by variants in the non-coding, regulatory regions that would be detectable by genome sequencing (316) and could be further assessed through technologies such as RNA-sequencing (317) and genome-wide methylation studies (319, 320).”
BackgroundState of the field: Differentiating intellectual disability from autism spectrum disorder
Thurm, A., Farmer, C., Salzman, E., Lord, C., & Bishop, S. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00526 · Cited by 267
Aref-Eshghi, E., Bend, E. G., Colaiacovo, S., Caudle, M., Chakrabarti, R., Napier, M., Brick, L., Brady, L., Carere, D. A., Levy, M. A., et al. (2019) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2019.03.008 · Cited by 201 · cited 3×
“As reference databases are bolstered (317), data sharing of variants and candidate genes increases (317, 323, 324), and additional technologies such RNA-sequencing and genome-wide methylation studies are integrated into testing algorithms (317, 319), our understanding of genes’ relationship to neurodevelopment disorde…”
BackgroundDevelopmental comorbidity in attention-deficit/hyperactivity disorder
Taurines, R., Schmitt, J., Renner, T., Conner, A. C., Warnke, A., & Romanos, M. (2010) · ADHD Attention Deficit and Hyperactivity Disorders · doi:10.1007/s12402-010-0040-0 · Cited by 198
Pizzo, L., Jensen, M., Polyak, A., Rosenfeld, J. A., Mannik, K., Krishnan, A., McCready, E., Pichon, O., Le Caignec, C., Van Dijck, A., et al. (2019) · Genetics in Medicine · doi:10.1038/s41436-018-0266-3 · Cited by 193 · cited 3×
“Many genetic underpinnings of NDD are characterized by variable expressivity, however, often leaving families with questions about recurrence and prognosis.”
BackgroundCopy number variants are frequent in genetic generalized epilepsy with intellectual disability
Mullen, S. A., Carvill, G. L., Bellows, S., Bayly, M. A., Berkovic, S. F., Dibbens, L. M., Scheffer, I. E., & Mefford, H. C. (2013) · Neurology · doi:10.1212/wnl.0b013e3182a95829 · Cited by 188
De Novo Coding Variants Are Strongly Associated with Tourette Disorder
Willsey, A. J., Fernandez, T. V., Yu, D., King, R. A., Dietrich, A., Xing, J., Sanders, S. J., Mandell, J. D., Huang, A. Y., Richer, P., et al. (2017) · Neuron · doi:10.1016/j.neuron.2017.04.024 · Cited by 187
Rosenfeld, J. A., Ballif, B. C., Torchia, B. S., Sahoo, T., Ravnan, J. B., Schultz, R., Lamb, A., Bejjani, B. A., & Shaffer, L. G. (2010) · Genetics in Medicine · doi:10.1097/gim.0b013e3181f0c5f3 · Cited by 169
Lesch, K.-P., Selch, S., Renner, T. J., Jacob, C., Nguyen, T. T., Hahn, T., Romanos, M., Walitza, S., Shoichet, S., Dempfle, A., et al. (2011) · Molecular Psychiatry · doi:10.1038/mp.2010.29 · Cited by 167
Improving IQ measurement in intellectual disabilities using true deviation from population norms
Sansone, S. M., Schneider, A., Bickel, E., Berry-Kravis, E., Prescott, C., & Hessl, D. (2014) · Journal of Neurodevelopmental Disorders · doi:10.1186/1866-1955-6-16 · Cited by 148
What are neurodevelopmental disorders?
Ismail, F. Y., & Shapiro, B. K. (2019) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000710 · Cited by 141
A Cross-Disorder Method to Identify Novel Candidate Genes for Developmental Brain Disorders
Gonzalez-Mantilla, A. J., Moreno-De-Luca, A., Ledbetter, D. H., & Martin, C. L. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.2692 · Cited by 139
International 22q11.2 Brain and Behavior Consortium, Davies, R. W., Fiksinski, A. M., Breetvelt, E. J., Williams, N. M., Hooper, S. R., Monfeuga, T., Bassett, A. S., Owen, M. J., Gur, R. E., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1103-1 · Cited by 139
Moreno-De-Luca, A., Evans, D. W., Boomer, K. B., Hanson, E., Bernier, R., Goin-Kochel, R. P., Myers, S. M., Challman, T. D., Moreno-De-Luca, D., Slane, M. M., et al. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.2147 · Cited by 137
Self-citationOwusu Obeng, A., Fei, K., Levy, K. D., Elsey, A. R., Pollin, T. I., Ramirez, A. H., Weitzel, K. W., & Horowitz, C. R. (2018) · Journal of Personalized Medicine · doi:10.3390/jpm8030024 · Cited by 131
One gene, many neuropsychiatric disorders: lessons from Mendelian diseases
Zhu, X., Need, A. C., Petrovski, S., & Goldstein, D. B. (2014) · Nature Neuroscience · doi:10.1038/nn.3713 · Cited by 131
Gudmundsson, O. O., Walters, G. B., Ingason, A., Johansson, S., Zayats, T., Athanasiu, L., Sonderby, I. E., Gustafsson, O., Nawaz, M. S., Jonsson, G. F., et al. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0599-y · Cited by 128
Larsson, H., Asherson, P., Chang, Z., Ljung, T., Friedrichs, B., Larsson, J.-O., & Lichtenstein, P. (2013) · Psychological Medicine · doi:10.1017/s0033291712001067 · Cited by 118
ASD, a Psychiatric Disorder, or Both? Psychiatric Diagnoses in Adolescents with High-Functioning ASD
Mazefsky, C. A., Oswald, D. P., Day, T. N., Eack, S. M., Minshew, N. J., & Lainhart, J. E. (2012) · Journal of Clinical Child & Adolescent Psychology · doi:10.1080/15374416.2012.686102 · Cited by 111
The impact of chromosomal microarray on clinical management: a retrospective analysis
Henderson, L. B., Applegate, C. D., Wohler, E., Sheridan, M. B., Hoover-Fong, J., & Batista, D. A. S. (2014) · Genetics in Medicine · doi:10.1038/gim.2014.18 · Cited by 71
Pathways from autism spectrum disorder diagnosis to genetic testing
Barton, K. S., Tabor, H. K., Starks, H., Garrison, N. A., Laurino, M., & Burke, W. (2018) · Genetics in Medicine · doi:10.1038/gim.2017.166 · Cited by 48 · cited 1×
“The specific testing algorithm varies between guidelines and consensus statements (214), and many recommendations predate the broad integration of exome sequencing into clinical care (Table 3).”
MethodOlszewski, A. K., Radoeva, P. D., Fremont, W., Kates, W. R., & Antshel, K. M. (2014) · Research in Developmental Disabilities · doi:10.1016/j.ridd.2014.08.034 · Cited by 37
Heterogeneity in clinical sequencing tests marketed for autism spectrum disorders
Hoang, N., Buchanan, J. A., & Scherer, S. W. (2018) · npj Genomic Medicine · doi:10.1038/s41525-018-0066-3 · Cited by 26 · cited 1×
“(156), comparison of ASD gene panels across 21 laboratories found that the number of genes included on ASD-related panels ranged from 11– 2,562 and only a single gene (MECP2) was included on all panels.”
Background
Cited by
Kouhashi, M., Yukawa, K., Yano, N., Hagemeijer, M. C., Hirata, S., Kambe, D., Yokoyama, A., Yoshida, A., Kora, K., de Ronde, C. J., et al. (2024) · Neurology Genetics · doi:10.1212/nxg.0000000000200161 · Cited by 3
Metadata
- Authors
- Savatt, J. M., & Myers, S. M.
- Venue
- Frontiers in Pediatrics
- Publisher
- Frontiers Media SA
- Published
- 2021-02-19
- Volume
- 9
- Pages
- 526779-526779
- ISSN
- 2296-2360 (ISSN-L)
- OpenAlex
- W3130715926
- Cited by
- 220
- References
- 56
- FWCI
- 16.74
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.